Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: J Urol. 2019 Nov 8;203(4):690–698. doi: 10.1097/JU.0000000000000644

Table 4.

Renal function outcomes at baseline, following neoadjuvant chemotherapy, and following surgery for each treatment arm.

Baseline Post-chemo Post-surgery
Arm A (aMVAC)
  Measured 30 30 29
  Median (range) CrCl (mL/min) 82.0 (53.7, 170.0) 75.5 (23.6, 203.0) 48.0 (25.9, 173.4)
  N, CrCl < 60 mL/min 2 6 20
  % (90% CI), CrCl < 60 mL/min 6.7 (1.2, 19.5) 20.0 (9.1, 35.7) 69.0 (52.1, 82.8)
  N, CrCl < 30mL/min 0 1 2
  % (90% CI), CrCl < 30 mL/min 0.0 (0.0, 9.5) 3.3 (0.2, 14.9) 6.9 (1.2, 20.2)
  Median (range) % change from baseline - −1.4 (−64.5, 71.1) −40.8 (−61.8, 17.2)
Arm B (GCa)
  Measured 6 6 6
  Median (range) CrCl (mL/min) 45.5 (37.0, 50.0) 48.1 (35.3, 91.4) 38.7 (18.9, 68.3)
  N, CrCl < 60 mL/min 6 5 5
  % (90% CI), CrCl < 60 mL/min 100 (60.7, 100.0) 83.3 (41.8, 99.1) 83.3 (41.8, 99.1)
  N, CrCl < 30 mL/min 0 0 2
  % (90% CI), CrCl < 30 mL/min 0.0 (0.0, 39.3) 0.0 (0.0, 39.3) 33.3 (6.3, 72.9)
  Median (range) % change from baseline - 10.6 (−4.6, 82.8) −12.9 (−61.5, 84.6)